Skip to main content
Premium Trial:

Request an Annual Quote

IP Roundup: Life Technologies, Theranos, Bioinfra

Premium

Life Technologies of Carlsbad, Calif., has received US Patent No. 8,435,395, "Methods and apparatus for measuring analytes using large scale FET arrays." Methods are claimed for producing large-scale, filed-effect-transistor arrays using conventional complementary metal–oxide–semiconductor processing techniques. According to the inventors, such arrays may be employed to detect a presence or concentration changes of various analyte types in a variety of chemical and biological processes.


Bioinfra of Seoul, South Korea, has received US Patent No. 8,435,748, "Method for monitoring, diagnosing, and screening cancer through measuring the concentration of des-R prothrombin activation peptide fragment F2 (des-R F2) in a serum." The patent claims a method of diagnosing cancer in an individual by measuring the expression of des-R-prothrombin activation peptide fragment F2 in blood, serum and plasma samples. According to the patent, the expression may be measured using a kit or biochip containing antibodies specifically binding to des-R prothrombin activation peptide fragment F2. By comparing the measured expression level of des-R-prothrombin activation peptide fragment F2 in the sample of the test subject with a normal subject, the inventors believe that they can determine if the subject has a cancer.


Theranos of Palo Alto, Calif., has received US Patent No. 8,435,738, "Systems and methods for multi-analysis." The patent describes a system that consists of modules mounted on a support structure. According to the patent, these modules include a sample preparation station, an assay station, an a detection station. The system is configured to perform sample preparation procedures and multiple types of assays, such as immunoassays, nucleic acid assays, receptor-based assays, and others. According to the patent, the multiple types of assays are performed with the aid of isolated units contained within the system.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.